DK3013855T3 - Mutante faktor VIII-sammensætninger og fremgangsmåder - Google Patents

Mutante faktor VIII-sammensætninger og fremgangsmåder Download PDF

Info

Publication number
DK3013855T3
DK3013855T3 DK14817835.3T DK14817835T DK3013855T3 DK 3013855 T3 DK3013855 T3 DK 3013855T3 DK 14817835 T DK14817835 T DK 14817835T DK 3013855 T3 DK3013855 T3 DK 3013855T3
Authority
DK
Denmark
Prior art keywords
methods
factor viii
mutant factor
viii compositions
compositions
Prior art date
Application number
DK14817835.3T
Other languages
English (en)
Inventor
Wenjing Cao
Biao Dong
Original Assignee
Xiao Weidong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiao Weidong filed Critical Xiao Weidong
Application granted granted Critical
Publication of DK3013855T3 publication Critical patent/DK3013855T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14817835.3T 2013-06-24 2014-06-24 Mutante faktor VIII-sammensætninger og fremgangsmåder DK3013855T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838867P 2013-06-24 2013-06-24
PCT/US2014/043777 WO2014209942A1 (en) 2013-06-24 2014-06-24 Mutant factor viii compositions and methods

Publications (1)

Publication Number Publication Date
DK3013855T3 true DK3013855T3 (da) 2021-01-11

Family

ID=52142603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14817835.3T DK3013855T3 (da) 2013-06-24 2014-06-24 Mutante faktor VIII-sammensætninger og fremgangsmåder

Country Status (14)

Country Link
US (3) US20160102133A1 (da)
EP (2) EP3904376B1 (da)
CN (1) CN105431451B (da)
CY (1) CY1124110T1 (da)
DK (1) DK3013855T3 (da)
ES (1) ES2837475T3 (da)
HR (1) HRP20210031T1 (da)
HU (1) HUE052074T2 (da)
LT (1) LT3013855T (da)
PL (1) PL3013855T3 (da)
PT (1) PT3013855T (da)
RS (1) RS61305B1 (da)
SI (1) SI3013855T1 (da)
WO (1) WO2014209942A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388739B (es) * 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
EA202190827A1 (ru) * 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
US20210228742A1 (en) 2018-04-27 2021-07-29 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using intraosseous delivery of a lentiviralgene construct
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2022211791A1 (en) * 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
EP4211153A4 (en) * 2021-11-25 2023-11-01 Sichuan Real&Best Biotech Co., Ltd. ENGINEERED HUMAN FVII1 WITH INCREASED SECRETION ABILITY AND COAGULATION ACTIVITY
WO2025180508A1 (en) * 2024-02-29 2025-09-04 Shanghai Vitalgen Biopharma Co., Ltd. Human factor viii variant expression cassettes and uses thereof for treating hemophilia a

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
ES2319745T3 (es) * 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface

Also Published As

Publication number Publication date
US20160102133A1 (en) 2016-04-14
PT3013855T (pt) 2021-01-13
EP3013855B1 (en) 2020-10-14
PL3013855T3 (pl) 2021-04-19
CN105431451B (zh) 2024-08-23
SI3013855T1 (sl) 2021-06-30
HUE052074T2 (hu) 2021-04-28
EP3904376A1 (en) 2021-11-03
CN105431451A (zh) 2016-03-23
LT3013855T (lt) 2021-01-25
EP3904376B1 (en) 2024-11-13
US20220144919A1 (en) 2022-05-12
US20190177399A1 (en) 2019-06-13
HRP20210031T1 (hr) 2021-05-14
CY1124110T1 (el) 2022-05-27
EP3013855A1 (en) 2016-05-04
ES2837475T3 (es) 2021-06-30
EP3013855A4 (en) 2017-12-13
RS61305B1 (sr) 2021-02-26
US11261234B2 (en) 2022-03-01
WO2014209942A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
GB2521022B (en) Compositions and methods
DK3074027T3 (da) Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
DK3494985T3 (da) Vaccinesammensætning omfattende mutant calreticulin
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
IL241112B (en) Methods and compositions for modification of hla
DK3043784T3 (da) Arylethere og anvendelser deraf
GB201308072D0 (en) Compositions and methods
EP2953474A4 (en) COMPOSITIONS AND METHODS
IL280725B (en) Neisseria meningitidis preparations and methods of their use
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
IL245470A0 (en) Methods and preparations for delayed immunotherapy
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
IL246518A0 (en) The compositions, including nanosheets, and methods to prevent friction wear and lubrication
DK3013855T3 (da) Mutante faktor VIII-sammensætninger og fremgangsmåder
GB201305813D0 (en) Compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
DK3223846T3 (da) Adjuvanssammensætninger og tilhørende fremgangsmåder
DK3191080T3 (da) Parenterale sammensætninger og anvendelser deraf
KR102216470B9 (ko) 천연물 조성물